Advertisement

Topics

Harpoon Therapeutics, Inc. Company Profile

05:07 EDT 20th July 2018 | BioPortfolio

Harpoon Therapeutics is an immuno-oncology company founded by Patrick Baeuerle, Ph.D., a pioneer in the development of T-cell engaging therapies, and MPM Capital. The company is focused on the discovery and development of novel T-cell engaging biologics for the treatment of cancer and other diseases. Harpoon Therapeutics created a novel T-cell recruiting drug discovery platform called TriTAC (tri-specific T-cell activating construct) to unleash the targeted cell-killing properties of a patient's own immune system through T-cell activation. This approach is being optimized to penetrate tissues and extend serum exposure, and has the potential to address a broad range of cancers, including solid tumors, and immunologic diseases. HPN424, a prostate-specific membrane antigen (PSMA)-targeting TriTAC biologic, is in development for the treatment of prostate cancer and is expected to enter a clinical trial in 2018. For more information, please visit www.harpoontx.com.


News Articles [776 Associated News Articles listed on BioPortfolio]

Trilobites: Using Harpoon-Like Appendages, Bacteria ‘Fish’ for New DNA

Seeing how microbes snatch new genetic material from their environment could help in the fight against antibiotic resistance.

Immunotherapy Pioneer and Serial Biotech Entrepreneur Patrick Baeuerle to Present Compelling Data from Harpoon Therapeutics’ Biotherapeutics Platform at the 2018 European Congress on Biotechnology

Patrick Baeuerle, Ph.D., a pioneer of T cell engaging therapies and executive partner at life sciences venture firm MPM Capital, will give a keynote presentation about next-genera...

Harpoon Therapeutics Launches Immuno-Oncology Pipeline With Compelling Data From Lead Programs at the 2018 American Association for Cancer Research (AACR) Annual Meeting

Preclinical Data Showcase New T Cell Engaging Platform (TriTAC™) and Lead Drugs, HPN424 and HPN536, Targeting Prostate Cancer and Other Solid Tumors Harpoon Therapeut...

Harpoon Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12032018] Prices from USD $250

SummaryHarpoon Therapeutics Inc Harpoon Therapeutics is a bio technology company that provides solutions for immuneoncology diseases. Its products portfolio comprises of HPN424, prostate specific anti...

Scientists watch bacteria 'harpoon' DNA to speed their evolution

(Indiana University) Indiana University researchers have directly observed for the first time how bacteria use appendages thousands of times thinner than a human hair to absorb DNA. The work could hel...

What You Need to Know About Indalo Therapeutics

Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics.

Technical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia Therapeutics, ...

www.wallstequities.com/registration Adaptimmune Therapeutics Shares in Abingdon, the UK headquartered Adaptimmune Therapeutics PLC rose slightly by 0.41%, ending Wednesday's trading session at $12...

Proteostasis Therapeutics Announces Withdrawal of Equity Offering Due to Market Conditions

About Proteostasis Therapeutics, Inc. Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (CF) and other di...

PubMed Articles [449 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Hitting HIV's Harpoon.

The HIV-1 fusion peptide is a target for broadly neutralizing antibodies. In a recent issue of Nature Medicine, Xu et al. (2018) provide proof-of-concept that vaccination with fusion peptide followed...

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Clinical Trials [146 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1244 Associated Companies listed on BioPortfolio]

Harpoon Therapeutics, Inc.

Harpoon Therapeutics is an immuno-oncology company founded by Patrick Baeuerle, Ph.D., a pioneer in the development of T-cell engaging therapies, and MPM Capital. The company is f...

Maverick Therapeutics Inc.

Maverick Therapeutics is pioneering the next generation of redirected T cell therapeutics in immuno-oncology. Maverick’s highly innovative platform is designed to deliver pot...

Harpoon Medical

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Harpoon Therapeutics, Inc." on BioPortfolio

We have published hundreds of Harpoon Therapeutics, Inc. news stories on BioPortfolio along with dozens of Harpoon Therapeutics, Inc. Clinical Trials and PubMed Articles about Harpoon Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Harpoon Therapeutics, Inc. Companies in our database. You can also find out about relevant Harpoon Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record